Molecular Characterization of Hepatitis C Virus Strain Circulated In Chronically Infected Patients in Abidjan (Cote-D’ivoire) (Published)
Viral hepatitis C (HCV) is a public health problem. The therapeutic management and in particular the duration of treatment depends on the viral genotype. HCV is poorly documented in the population and there are few data on the different genotypes and subtypes of HCV circulating in Côte d’Ivoire. In this context, the main objective of this study was to study the genetic variability of the HCV virus in infected patients in Abidjan. We conducted a cross-sectional study at CIRBA from June 2015 to June 2017 which included adult patients with a Viral Load > 1000 IU/mL. HCV genotyping was performed by amplification of the NS5B region followed by sequencing with an ABI 3130 sequencer (Applied Biosystems, Courtaboeuf, France). Phylogenetic trees were produced using MEGA 7 software and genotypes were confirmed using online software (http://hcv.geno2pheno.org). In this study 94 subjects were included. The genotypes encountered were genotypes 1, 2 and 4 with a prevalence of 46%, 52% and 2% respectively. These strains were divided into 17 subtypes genotype 1 : 6 subtypes 1a, 1b, 1c, 1d, 1i, 1k, genotype 2 : 9 subtypes 2a, 2b, 2c, 2c/k, 2f, 2j, 2k, 2l, 2r and 2 subtypes 4f and 4r for genotype 4. The study allowed the implementation of a genotyping technique and monitoring showed that genotypes 1 and 2 are predominant in Côte d’Ivoire. The circulation of genotype 4 is noted.
Keywords: HCV, Sequencing, Treatment., genotype.
Interferon Inducible Protein-10 Level and Il28b Gene Polymorphism as Predictors of the Response to Pegylated Interferon / Ribavirin Therapy in Egyptian Hcv Patients (Published)
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and hepatocellular carcinoma worldwide. The highest prevalence of HCV infection was reported to occur in Egypt. It is crucial to determine the predictors of Sustained Viral Response (SVR) to Pegylated Interferon (peg-INF) / Ribavirin (RBV) therapy in chronic HCV Egyptians, in order to select the patients who will get benefit from this costly therapy that has frequent side effects. Pretreatment serum interferon Inducible Protein-10 (IP-10) level measurement and genotyping for IL28B rs12979860 polymorphism, were carried out on 82 Egyptian chronic HCV patients receiving peg-INF/ RBV dual therapy for 48 weeks. It was revealed that patients with SVR had lower baseline IP-10 level. The baseline IP-10 level with the best sensitivity and specificity for identifying SVR was 499.02 pg/ml, with 100% specificity and 82% sensitivity. Moreover, the response rates to this dual therapy were 86.2%, 52.9%, 0.0% for genotypes CC, CT, and TT of the IL28B rs12979860 polymorphism respectively. So it can be said that carriage of a C allele is favorably associated with treatment response. Also a statistically significant lower serum IP-10 baseline level was found in the homozygous carriers of favorable CC genotype as compared with carriers of CT and TT genotypes. In conclusion, baseline serum IP-10 and genotyping for IL28B rs12979860 polymorphism are of significant value in predicting the response to peg-INF/ RBV dual therapy in Egyptian chronic HCV infection patients
Keywords: HCV, IL28B, IP-10, Interferon, ribavirin., sustained virological response
Interferon Inducible Protein-10 Level and IL28B Gene Polymorphism as predictors of the Response to Pegylated Interferon / Ribavirin therapy In Egyptian HCV Patients (Published)
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and hepatocellular carcinoma worldwide. The highest prevalence of HCV infection was reported to occur in Egypt. It is crucial to determine the predictors of Sustained Viral Response (SVR) to Pegylated Interferon (peg-INF) / Ribavirin (RBV) therapy in chronic HCV Egyptians, in order to select the patients who will get benefit from this costly therapy that has frequent side effects. Pretreatment serum interferon Inducible Protein-10 (IP-10) level measurement and genotyping for IL28B rs12979860 polymorphism, were carried out on 82 Egyptian chronic HCV patients receiving peg-INF/ RBV dual therapy for 48 weeks. It was revealed that patients with SVR had lower baseline IP-10 level. The baseline IP-10 level with the best sensitivity and specificity for identifying SVR was 499.02 pg/ml, with 100% specificity and 82% sensitivity. Moreover, the response rates to this dual therapy were 86.2%, 52.9%, 0.0% for genotypes CC, CT, and TT of the IL28B rs12979860 polymorphism respectively. So it can be said that carriage of a C allele is favorably associated with treatment response. Also a statistically significant lower serum IP-10 baseline level was found in the homozygous carriers of favorable CC genotype as compared with carriers of CT and TT genotypes. In conclusion, baseline serum IP-10 and genotyping for IL28B rs12979860 polymorphism are of significant value in predicting the response to peg-INF/ RBV dual therapy in Egyptian chronic HCV infection patients
Keywords: HCV, IL28B, IP-10, Interferon, ribavirin., sustained virological response